RAD51D is an inclusion criterion in 17 clinical trials for prostate carcinoma, of which 13 are open and 4 are closed. Of the trials that contain RAD51D status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].

Olaparib has evidence of efficacy in patients with RAD51D mutation in prostate carcinoma [4].

RAD51D is an inclusion criterion in 35 clinical trials for malignant solid tumor, of which 29 are open and 6 are closed. Of the trials that contain RAD51D status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 8 are phase 1/phase 2 (5 open), and 13 are phase 2 (13 open) [4].

RAD51D is an inclusion criterion in 24 clinical trials for breast carcinoma, of which 20 are open and 4 are closed. Of the trials that contain RAD51D status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [4].

RAD51D is an inclusion criterion in 18 clinical trials for ovarian carcinoma, of which 14 are open and 4 are closed. Of the trials that contain RAD51D status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51D is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain RAD51D status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [4].

RAD51D is an inclusion criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain RAD51D status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51D is an inclusion criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51D status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51D is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain RAD51D status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51D status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51D status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51D status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

RAD51D is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51D status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [4].

RAD51D is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51D status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51D status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51D status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51D status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51D status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51D is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].